Probiotics Show Uneven Benefit in Three Skin Diseases

In a 12-week placebo-controlled trial, infants with mild-to-moderate atopic dermatitis showed no significant improvement in SCORAD scores with Lactobacillus rhamnosus GG. Symptoms improved in both groups, while severity, rescue medication use and immunologic markers did not differ significantly.

That null result forms part of the evidence base for a 2026 review by Sharma, Nhokwara, Singh, Bala and Kamra in Immunity, Inflammation and Disease (14(10), e70574; DOI 10.1002/iid3.70574). The paper, Microbiome-Immune Crosstalk in Inflammatory Skin Diseases: Mechanisms and Therapeutic Potential of Probiotics, compares atopic dermatitis, acne vulgaris and psoriasis side by side.

The authors argue that inconsistent probiotic responses do not disprove the gut-skin axis. They show why the field should ask when and under what conditions microbial effects become clinically meaningful, rather than debating whether gut microbes influence skin at all.

The review applies a fixed sequence to each disease: observed microbiome findings, proposed biological pathway, strength of evidence, probiotic trial outcomes and remaining uncertainty. It also distinguishes microbiota, the living microbial communities, from microbiome, their collective genetic content and functional capacity. That distinction matters when sequencing and metagenomics connect microbial taxa and metabolic pathways with disease phenotypes.

Disease biology determines the meaning of microbial shifts

Observational studies associate atopic dermatitis with reduced Faecalibacterium prausnitzii and Bifidobacterium species, plus increased Escherichia coli and Clostridioides difficile. Because atopic dermatitis centers on barrier dysfunction and impaired immune tolerance, researchers propose that reduced short-chain fatty acid production and weaker immune tolerance link gut dysbiosis with epithelial inflammation and heightened allergen sensitivity. Not all patients share these microbial or metabolic patterns.

Other trials using Bifidobacterium species or multistrain formulations reported SCORAD reductions, particularly in children, while several studies with similar strains found no significant benefit. Early-life interventions produced more consistent effects than studies in older children or adults. The review therefore treats probiotic response as biologically and age dependent rather than uniform.

Acne: metabolic signaling appears to outweigh the microbiome

Agamia and colleagues studied 60 patients and reported elevated serum IGF-1 plus altered skin expression of FoxO1 and mTOR in people with acne relative to controls. Dietary patterns associated with acne, including high glycemic load and low fiber intake, can alter microbial composition and metabolite production, potentially affecting insulin signaling and inflammatory tone.

Similar microbial profiles did not consistently produce similar clinical outcomes, suggesting that microbiome effects act as modulators rather than primary drivers. In one 12-week trial, Lacticaseibacillus rhamnosus CECT 30031 combined with Arthrospira platensis improved the clinical course; other trials reported minimal change over similar durations. Trials that added dietary modification tended to show more consistent improvement.

Psoriasis: a systemic immune network remains difficult to shift

Psoriasis primarily involves systemic immune activation through IL-17 and TNF pathways, with elevated IL-17, IL-18 and IFN-gamma. Studies report reduced Akkermansia muciniphila in patients and bacterial DNA in peripheral blood during active disease, suggesting microbial translocation across a disrupted gut barrier.

Experimental models show reductions in inflammatory markers and lesion severity after probiotic treatment, but human trials split between modest PASI improvements and no significant probiotic-control differences. The review therefore argues that gut-targeted intervention alone may not sufficiently modify the dominant IL-17/TNF inflammatory network.

Stress can modify the axis, not replace other causes

Early observations linked emotional stress with acne severity. Stress activates the hypothalamo-pituitary-adrenal axis and can alter cortisol signaling, potentially increasing sebaceous lipogenesis and lowering the threshold for inflammatory responses to Cutibacterium acnes. Stress alone does not cause acne in every person; baseline androgen and IGF-1 activity, diet, genetics and pre-existing gut and skin microbiota shape clinical expression.

In atopic dermatitis, stress associates with increased pruritus and barrier disruption. In psoriasis, neuroendocrine influences exist but rank behind sustained immune activation as a driver of disease progression.

Strain selection may explain conflicting trial results

Strains grouped under Lactobacillus or Bifidobacterium can differ substantially in function: some generate more short-chain fatty acids, while others more strongly regulate immune signaling. Trials using different strains or combinations cannot be directly compared, and a positive result may depend on functional properties that another formulation lacks.

The authors favor selecting strains against disease-relevant mechanisms. They also identify postbiotics and synbiotics as potentially more targeted approaches, although their role in dermatological conditions remains underexplored.

What does this change for patients?

It changes the clinical question from whether probiotics work to which formulation may work in which disease and patient. Atopic dermatitis appears to have the strongest overlap between microbiome pathways and central disease mechanisms, so responses may be more consistent, particularly in early-life cohorts. In acne and psoriasis, metabolic and systemic immune processes dominate; the review frames microbiome-targeted strategies as adjunctive or context-dependent rather than universal therapy.

Neither the positive SCORAD studies nor the modest PASI trials justify a single standard probiotic prescription. The authors call for standardized outcome measures, clearer characterization of formulations and better reporting of patient characteristics. Short trials may also capture transient inflammatory changes without establishing durable disease modification.

Future trials that align characterized strains with disease-specific mechanisms, use standardized outcomes and measure whether benefits persist could determine whether today’s patchwork reflects poorly matched trials or a genuinely selective treatment response.